Sr. Manager Market Access
Pubblicato il 05-10-2026 - Shionogi Europe in Roma
Senior Manager, Market Access & HTA Italy At Shionogi, we are committed to improving and extending patients’ lives through innovation, collaboration and a clear focus on access. Our Market Access teams work across the organisation and with external stakeholders to demonstrate value and help ensure that patients can agevolazioni from the treatments they need. We are now seeking a Senior Manager, Market Access & HTA Italy to lead the development and execution of market access, pricing, reimbursement and health technology assessment strategies for Italy. This role will connect the Italian affiliate with the European Market Access & Policy organisation and support both in-line and pipeline products.
La descrizione completa del lavoro illustra tutte le competenze, l'esperienza pregressa e le qualifiche che i candidati dovrebbero possedere.
Why Join Shionogi? Shionogi offers a purpose-driven, agile and collaborative environment where employees are empowered to make a meaningful impact. This role provides the opportunity to shape access strategy in Italy,
influence launch readiness and lifecycle planning, and build trusted relationships with payers, institutions, scientific societies and other key stakeholders.
Job Requirements Market Access, Pricing & HTA Strategy
- Develop, manage and execute Market Access and HTA strategies for Italy, aligned with European and global priorities.
- Lead pricing, reimbursement and HTA activities, including dossiers, payer value propositions, pricing strategy and negotiation materials.
- Provide strategic input into launch readiness and lifecycle management for in-line and pipeline products.
- Conduct health economics and outcomes research to support market access strategy and value demonstration.
Stakeholder Engagement & External Environment
- Build and maintain effective relationships with AIFA, regional payers, institutions and scientific societies.
- In collaboration with Medical, support timely real-world evidence initiatives and disease